To address the limitations of triptolide's pharmacokinetics and toxicity, a novel antibody–drug conjugate, Cet-triptolide, is developed for targeted delivery to EGFR-overexpressing cancers, showing enhanced tumor-specific cytotoxicity and reduced toxicity compared to triptolide or cetuximab alone [987]. Here, EGFR is linked to neoplasm.